Seral Cristina, Carryn Stéphane, Tulkens Paul M, Van Bambeke Françoise
Unité de Pharmacologie Cellulaire et Moléculaire, Université Catholique de Louvain, UCL 73.70 Avenue E. Mounier 73, B-1200 Brussels, Belgium.
J Antimicrob Chemother. 2003 May;51(5):1167-73. doi: 10.1093/jac/dkg223. Epub 2003 Apr 14.
Antibiotic efflux pumps expressed in eukaryotic cells can decrease the intracellular accumulation of the corresponding drugs and therefore impair their activity against intracellular bacteria. We have investigated whether verapamil (an inhibitor of P-glycoprotein) and gemfibrozil (an inhibitor of multidrug resistance proteins (MRP) and other organic anion transporters), can modulate the intracellular activity of azithromycin and ciprofloxacin against Listeria monocytogenes and Staphylococcus aureus in J774 macrophages. In parallel, we have measured the cell accumulation and subcellular distribution of both drugs. Antibiotics were used at equipotent extracellular concentrations (from 0.5 x to 10 x MIC) to allow for pharmacological comparisons. Azithromycin was bacteriostatic against L. monocytogenes and slightly bactericidal against S. aureus. Verapamil did not improve the maximal activity of azithromycin but allowed it to reach a similar effect at extracellular concentrations about seven-fold lower in both models. Azithromycin was predominantly localized in cell granules (66%), the remainder being in the cytosol and in the 'nuclei/unbroken cells' fraction. Verapamil increased the cellular accumulation of azithromycin by almost 2.4-fold without modifying its subcellular distribution. Ciprofloxacin displayed a strong concentration-dependent bactericidal activity in both models. Gemfibrozil increased ciprofloxacin activity almost 2.5-fold against L. monocytogenes, but not against S. aureus. Ciprofloxacin was predominantly (65%) distributed in the cytosol. Gemfibrozil increased ciprofloxacin total accumulation by approximately 2.4-fold, but the excess was only found in the cytosol. Inhibition of efflux pumps may be a useful strategy to improve antibiotic efficacy against intracellular bacteria when increased accumulation can be obtained in the compartment where bacteria sojourn.
在真核细胞中表达的抗生素外排泵可减少相应药物的细胞内蓄积,因此会削弱其对细胞内细菌的活性。我们研究了维拉帕米(一种P-糖蛋白抑制剂)和吉非贝齐(一种多药耐药蛋白(MRP)及其他有机阴离子转运体的抑制剂)是否能调节阿奇霉素和环丙沙星在J774巨噬细胞中对单核细胞增生李斯特菌和金黄色葡萄球菌的细胞内活性。同时,我们测定了这两种药物的细胞蓄积及亚细胞分布。使用等效细胞外浓度(0.5倍至10倍最低抑菌浓度)的抗生素以进行药理学比较。阿奇霉素对单核细胞增生李斯特菌具有抑菌作用,对金黄色葡萄球菌有轻微杀菌作用。维拉帕米并未提高阿奇霉素的最大活性,但在两个模型中,使阿奇霉素在约低7倍的细胞外浓度下就能达到类似效果。阿奇霉素主要定位于细胞颗粒(66%)中,其余分布在胞质溶胶和“细胞核/未破碎细胞”部分。维拉帕米使阿奇霉素的细胞蓄积增加了近2.4倍,且未改变其亚细胞分布。环丙沙星在两个模型中均表现出强烈的浓度依赖性杀菌活性。吉非贝齐使环丙沙星对单核细胞增生李斯特菌的活性提高了近2.5倍,但对金黄色葡萄球菌没有作用。环丙沙星主要(65%)分布在胞质溶胶中。吉非贝齐使环丙沙星的总蓄积增加了约2.4倍,但过量部分仅存在于胞质溶胶中。当能在细菌寄居的区室中实现蓄积增加时,抑制外排泵可能是提高抗生素对细胞内细菌疗效的一种有用策略。